SanBio Co (JP:4592) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SanBio Co., Ltd. experienced a minor setback in the first production run of AKUUGO, a stem cell therapy for brain injury, as it did not fully meet specification standards. Despite this, the company remains optimistic as key aspects like yield were compliant, and they have commenced a second production run. The delay is expected to minimally impact this fiscal year’s financial performance.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.